|
Codes: At the end of each Update & Sneak, there are three codes. They have a rating from 1 to 10. Those numbers reflect my personal opinion. Please -- do not take action based on my opinion alone. Do four things before taking action: (1) Read my original writeup to get an overall feel (in the case of updates on recommendations); (2) Get the latest 10-Q, 10-K, corporate profile, & news releases; you can access them at www.wallstreetcorner.com on the Internet; (3) Study them; & (4) Call a key member of management to get a final impression. If anything bothers you regarding that call, pass. There are lots of situations. Do not invest unless everything about a situation feels good to you. "R" stands for "Risk Rating." A "1" means I view the situation as having an extreme amount of risk. A "10" means very low risk -- a much sounder, more financially stable situation. You'll see hardly any with a "1" or "10" rating. I chose "10" to mean lower risk so the higher the number after each of the three codes, the more favorable the rating. "M" stands for "Midterm Appreciation Potential." A "1" means I view the situation as having a small degree of midterm ("mid-term" is six to 12 months) potential. A "10" means really outstanding midterm potential. "L" stands for "Long-term Appreciation Potential." A "1" means I view the situation as having a small degree of long-term ("long-term" is over one year) potential. A "10" means really outstanding long-term potential. Actrade International Ltd. (NASDAQ/ACRT -- CS Sneak 10/95 & 1/99) announced it secured a five year, $25 million revolving credit facility with ING Barings. This allows it to expand its Trade Acceptance Draft (TAD) program. On 3/30/99, it announced a $10 million revolving credit facility with Summit Bank, which allows further TAD expansion. ACRT also signed a marketing agreement with Excite, Inc. (NASDAQ/XCIT) to launch ACRT's on-line advertising. Call Mitch Menik @ 212-563-1036; fax 212-563-3271, or write 7 Penn Plaza, Suite 422, New York, NY 10001. www.acrt.com. [R-7; M-7; L-8] Action Products International, Inc. (NASDAQ/-APII -- CS 12/98) reported FY 98 sales of $5,868,800 compared to $5,864,300 for '97. However, on the basis of continuing toy & book product lines (its core products), this reflects an increase of about 35%. Call CEO Ronald Kaplan @ 352-687-2202 or IR director Rebecca Garrett @ 352-680-3516; fax 352-687-2858, or write 344 Cypress Rd., Ocala, FL 34472-3108. Email: becky@apii.com. www.apii.com. [R-7; M-6; L-8] Advantage Marketing Systems, Inc. (NASDAQ/AMSO -- CS Sneak 1/99) reported Q4 (12/31/98) net income of $167,626 ($0.04/share), compared to a net loss of $22,457 in Q4 1997. Net sales increased 48.1% to $3,786,888 compared to $2,556,906 in Q$ 1997. Net income was up 218.4% to $414,048 for FY 1998, up from $130,026 in 1997. Call 800-426-4267 (ext 4916 for Curt Wilson, or ext. 4903 for Roger Baresel), fax 405-843-4935, or write 2601 NW Expressway, Suite 1210W, Oklahoma City, OK 73112. [R-8; M-8; L-9] Alexa Ventures Inc. (VSE/AXA.V CS Sneak 2/97) reported FY '98 sales of $22,734,000 & gross margin of $3,292,000 vs. $3,734,000 & $1,169,000 respectively for FY '97. Call CEO Gerry Racicot @ 519-273-0503, fax 519-273-1684 or write 818 Erie St., Stratford, Ontario Canada N4Z 1A2. [R-5; M-7; L-8] American Bio Medica Corp. (NASDAQ/ABMC -- CS Sneak 12/98) announced its Portuguese distributor signed an exclusive agreement with that country's professional basketball league to use ABMC's patented Rapid Drug ScreenTM kits for random on-site testing of its players. It announced 3/29/99 an exclusive agreement with SIMYACI in Istanbul, Turkey to distribute ABMC's kits for random on-site testing to that country's correctional system. ABMC also announced Q3 revenue (1/31/99) of $2,061,000, up 442% from Q3 last year. Call CEO Stan Cipkowski @ 800-227-1243, fax 518-329-4256, or write 102 Simons Rd., Ancramdale, NY 12503 [R-6; M-7; L-8] |
American Resource & Development, Inc. (OTC Bulletin Board/ADCO -- CS Sneak 5/98) reported its Pacific Print Works subsidiary achieved its first profit in nearly two years for the month of 1/99. Q3 revenue for ADCO rose 138%. Call CEO Will Papenfuss @ 503-492-1500, fax 503-665-1914, or write 2035 NE 181st St., Portland, OR 97230. www.ardcoinfo.com [R-6; M-7; L-8] California Micro Devices Corp. (NASDAQ NMS/CAMD -- CS 10/98) & Flip Chip Technologies (FCT) announced a non-exclusive technology license agreement that provides CAMD with access to FCT's Ultra CSPTM manufacturing technology. This will enhance CAMD's line of Integrated Passive Devices (IPD's) in chip scale packages & provides a more cost-effective means of satisfying the increasing demand for high-performance, high-density components. Call IR @ 800-325-4966; fax @ 408-263-7846, or write 215 Topaz St., Milpitas, CA 95035. E-mail: kimk@calmicro.com. www.calmicro.co-m. [R-7; M-7; L-8] Catalytica, Inc. (NASDAQ/CTAL -- CS Sneak 11/98) reported revenues for FY '98 of $375,156,000, more than double FY '97. Net income for the year was $20,763,000 or $0.33/share vs. $310,000 or a loss of $0.10/share after the EPS adjustment re the repurchase of Series B common stock. Call Lloyd Baylis @ 650-960-3000, fax 650-960-0127, or write 430 Ferguson Dr., Mountain-view, CA 94043. [R-7; M-7; L-9] CECO Environmental Corp. (NASDAQ/CECE -- CS 9/97) announced its Busch Co. division received an order from National Steel (NYSE/NS) for CECO's $500,000 patented JET*STARTM Strip Cooling System for NS' Midwest Division in Portage, IN. CECE also announced on 3/29/99 a new banking relationship with PNC Bank (NYSE/PNC), increasing its credit line from $2 million to $5 million, a $625,000 term loan, & a $787,000 mortgage loan. In addition, PNC Bank will assist CECE in consummating future acquisitions through a committed $2 million acquisition line of credit & an express willingness to consider providing financings for larger acquisitions on terms satisfactory to the Bank. Call CECO @ 416-593-6543 or their IR firm @ 303-850-7896. [R-6; M-7; L-8] Empyrean Bioscience, Inc. (formerly Emperyean Diagnostics -- OTC Bulletin Board/EMDG -- CS 6/98) delivered its first shipment of its new Preventx hand sanitizing products to its strategic partner Integrated Commercialization Solutions (ICS). In a single day, 2/25/99, 2.1 million shares of EMDG were traded & finished the day up $0.37/share. Call CEO Stephen Hayter @ 602-879-6935, or write 2238 West Lone Cactus Dr., Suite 200, Phoenix, AZ 85027. [R-6; M-7; L-8] Galaxy Foods Company (NASDAQ/GAXCD - formerly GALX -- CS 7/97) announced its sponsorship of the Relay For Life, a key fund raising effort of the American Cancer Society. Call Rebecca Barksdale @ 407-855-5500 Ext. 105 or write 2441 Viscount Row, Orlando, FL 32809. [R-7; M-6; L-7] Hemispherx Biopharma, Inc. (AMEX/HEB -- CS Sneak 12/96) is working to develop the AmpligenR family of RNA drugs for the treatment of viral diseases & certain cancers. A lot has happened since my first coverage of HEB. Ampligen, a parental drug product, is in advanced human clinical development for various therapeutic indications. HEB has one of the largest patent portfolios in the biotechnology industry. A total of 328 patents have been issued; 176 in the European Union, 66 in the Pacific Rim, 57 in non-European, non-Pacific Rim countries, & 27 in the U.S. Here are some highlights: June 1997: Received FDA approval for a Phase II, Chronic Fatigue Syndrome (CFS)/treatment protocol for Ampligen with cost recovery. HEB has five clinical sites across the U.S. Similar Phase II cost recovery programs were set up in Canada, Brussels, & Belgium. .... October 1998: Initiated a Phase III ME/CFS clinical trial in six sites across the country. An additional three sites have been pre-certified by the FDA. .... October 1998: Started treating patients with ready-to-use liquid Ampligen. The availability of the ready-to-use liquid form offers multiple conveniences to the end user. The liquid form of the Ampligen was submitted to the FDA during the Q3 of 1998 for full review & comments prior to its use in the cost-recovery program. Lions Gate Entertainment Corp. (AMEX/TSE/LGF -- CS 11/98) launched a new daily animated series "Mega Babies" with 26 half-hour episodes on the Fox Family Channel. It follows the out-of-this-world, fast-paced adventures of three extraordinary orphans who gain immense ...continued on next page, click here |
|
|
|
Disclaimer: The public companies featured in the Corporate Profiles listed in the "Special Situation" section on the Home Page of www.WallStreetCorner.com are our regular clients. Each such client pays an annual cash fee of $12,000, or alternatively, a monthly cash fee of $495 plus a negotiated number of Form 144 restricted shares for our service. We on rare occasions accept free-trading shares, but we usually hold such shares for the long pull - we do not engage in trading. Such fees are disclosed as part of the Corporate Profile prepared and posted on the particular company involved. The basic coverage provided to such clients primarily includes the preparation of their Corporate Profile, posting it here at WallStreetCorner.com, and the distribution of email alerts to our international database of investors and financial professionals when their Profile is initially posted, and each time their Profile is subsequently updated. We expect our clients to work with us in a team effort by calling us each time they have achieved a significant milestone. We then update their Profile and issue an additional email alert to our totally opt-in email database (as of July 2008, members of that database are from over 96 countries). The email distributions we make are a key element of our service -- those, as well as the updated Corporate Profile are what together are designed to achieve a gradual buildup of new shareholders who generally hold for the long term. If you are an officer at a public company and want the exposure afforded at WallStreetCorner.com, email Larry at up415@aol.com or call him at 843-645-2729. Information displayed by WallStreetCorner in its Corporate Profiles, and in its editorial or other columns, does not constitute an offer to buy, sell, or trade a security of any kind, including stock. Larry Oakley, and/or WallStreetCorner.com, Inc., does not recommend that any person, institution, or other entity make any decisions or form any opinions, etc. based on the information on this site. All visitors to this site are urged to do two things before investing in any stock: (1) Call the company and ask questions -- if there is anything you do not like regarding such call, pass -- our goal is to bring you a selection of what we feel are growth situations with good long-term appreciation potential, but you must accept the responsibility of making your own decisions regarding which situations to invest in -- do not give up that responsibility; and (2) Consult a qualified financial professional before taking any actions in regards to buying, selling, or trading securities (stocks or other forms of equity). Companies covered in Conservative Speculator, a newsletter accessed from WallStreetCorner, or in any of Larry Oakley's other editorial venues ("Opinion," "Stock Pick," "Comment," and "Bold Ventures" columns, and in any other editorial venue to which Larry contributes) do not pay for such editorial coverage; the companies Larry covers editorially have never, do not now, and never will be charged for editorial coverage. The only paid portions of WallStreetCorner.com are the Profiles and email distributions (email distributions are a part of the client's package, but occasionally are paid for separately by non-clients - if a non-client wants to utilize our email distributions, the cost is $2,000 for the first distribution, $1,500 for the second, $1,000 for the third, and $500 for all subsequent distributions made for the same company). On occasion, Larry Oakley shares his opinion regarding a private company or its product or service. Bear in mind that nothing at that special section is an investment possibility. To see that section, click where on the home page it says: "Click here to access our Special Emerging Growth Situations." See the introductory portion of that special section for additional information regarding the material covered there. |
|
|
WallStreetCorner.com |
